HIGHLIGHTS
- who: RNF et al. from the Institute for Advanced Biosciences, Grenoble Alpes University, CNRS University Nijmegen, Nijmegen, the Netherlands have published the research work: CANCER DISCOVERY, in the Journal: (JOURNAL) of 28/08/2022
- what: The authors seek to identify mechanisms that promote SCLC tolerance to platinum-containing drugs such as cisplatin and alkylating agents such as cyclophosphamide (CP). The authors propose a rationale for targeting SMYD3 as a novel strategy to overcome the development of resistance in SCLC. The authors aimed to investigate if this newly discovered SMYD3- RNF113 methylation event is physiologic and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.